ArticleEuropean journal of medical research2026
METTL3 promotes pancreatic cancer immune escape by m6A modification of lncRNA AFAP1-AS1 to enhance EGR2 stability.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPancreatic cancer (PC) exhibits significant immune evasion. The roles of N6-methyladenosine (m6A) RNA modification and long non-coding RNAs (lncRNAs) in PC immunity are emerging. We aimed to elucidate the function and mechanism of METTL3-mediated m6A modification of lncRNA AFAP1-AS1 in PC progression and immune escape, focusing on its interaction with early growth response 2 (EGR2).
methodsExpression of METTL3, AFAP1-AS1, and EGR2, along with AFAP1-AS1 m6A levels, were measured in human PC tissues/cell lines via quantitative reverse transcription PCR, Western blot, and methylated RNA immunoprecipitation. Functional assays (proliferation, invasion, CD8
resultsMETTL3, AFAP1-AS1, and EGR2 were significantly upregulated in PC, where AFAP1-AS1 exhibited increased m6A modification and correlated with poor prognosis. METTL3 directly mediated AFAP1-AS1 m6A modification, enhancing its stability through the m6A readers YTHDF2 and IGF2BP1. Functionally, AFAP1-AS1 promoted PC cell malignancy and immune evasion, characterized by resistance to T cell killing, suppressed T cell function, and increased programmed death-ligand 1 (PD-L1). Mechanistically, AFAP1-AS1 stabilized EGR2 mRNA through direct binding, elevating EGR2 protein expression. ChIP assays confirmed that EGR2 directly binds to the promoters of PD-L1 and Snail. EGR2 knockdown phenocopied AFAP1-AS1 knockdown effects, and EGR2 overexpression rescued the AFAP1-AS1 knockdown phenotype. In vivo, METTL3 depletion inhibited tumor growth and enhanced anti-tumor immunity, characterized by decreased Tregs and M2 macrophages infiltration, effects partially reversed by EGR2 restoration.
conclusionMETTL3 enhances AFAP1-AS1 stability via m6A modification recognized by YTHDF2 and IGF2BP1, which subsequently increases EGR2 expression by improving its mRNA stability. EGR2 directly activates transcription of immune checkpoint and epithelial-mesenchymal transition (EMT)-related genes. This METTL3/AFAP1-AS1/EGR2 signaling axis drives PC malignancy and immune resistance, offering potential therapeutic targets for PC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.